Cytodyn Inc (CYDY)

[docj]

https://www.walshmedicalmedia.com/open-access/leronlimab-a-humanized-anticcr5-monoclonal-antibody-ameliorates-hepatic-fibrosis-in-two-preclinical-fibrosis-mouse-model.pdf

CONCLUSION
In conclusion, the present preclinical findings demonstrate that
leronlimab treatment is associated with a significant reduction in
liver fibrosis across multiple mouse models. These results support
further investigation of leronlimab, either as monotherapy or in
combination with other agents, for chronic liver diseases with
fibrosis of varied etiologies